JERUSALEM — Teva Pharmaceutical Industries Ltd. has released generic versions of Actavis’ Actonel tablets, an osteoporosis medication, and of Amneal’s Lomedia 24 Fe, a women’s contraceptive, in the United States.
Teva said Monday that its generic equivalent of Actonel (risedronate sodium) comes in dosages of 5 mg, 30 mg and 35 mg and that the company was the first to file, making the product eligible for 180 days of market exclusivity.
Risedronate sodium tablets are used to treat or prevent osteoporosis in women after menopause. The medication helps increase bone mass and reduce the chance of having a spinal or nonspinal fracture. In addition, risedronate sodium tablets are used to treat or prevent osteoporosis in men or women taking corticosteroid medicines and to treat Paget’s disease of the bone.
Teva noted that its risedronate sodium tablets are the second approved product to treat osteoporosis in the company’s generic portfolio.
Actonel tablets marketed by Actavis had annual U.S. sales of $157 million through December 2014, according to IMS Health data reported by Teva.
Teva announced the U.S. availability of generic Lomedia 24 Fe (norethindrone acetate and ethinyl estradiol tablets 1 mg/20 mcg and ferrous fumarate tablets 75 mg) on Friday. The product is being launched under the name Junel Fe 24 in the U.S.
With the addition of Junel Fe 24, Teva said it now offers women a line of nearly 30 generic contraceptive products.
Lomedia 24 Fe marketed by Amneal had U.S. sales of about $32 million in the year through December, according to IMS Health figures cited by Teva.
Comments are closed.